Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Akeso Biopharma
Biotech
China biotechs ‘reshaping’ US biopharma: Jefferies report
In 2025's Q1, 32% of outlicensing biotech deal value occurred in China versus 21% reported in both 2024 and 2023, according to Jefferies.
Gabrielle Masson
Jul 14, 2025 2:30pm
Fierce Pharma
Summit in high-stakes deal talks with AstraZeneca: Bloomberg
Jul 7, 2025 10:45am
Akeso's bispecific notches ph. 3 victory against gastric cancer
Nov 7, 2023 10:50am
Summit bets $5B that Akeso's bispecific will reach cancer peak
Dec 6, 2022 12:50pm
